1.Expression of Plk1, Cyclin B1 and p21WAF1 in cervical carcinoma and their clinical signifi-cance
Yunna QIN ; Deming HE ; Debao ZHUANG ; Lu YE ; Yinghui DENG ; Hailian LUO ; Xiaohong YU
Chinese Journal of Clinical and Experimental Pathology 2015;(4):385-389
Purpose To investigate the expression of polo-like kinase 1 (Plk1) and Cyclin B1, p21WAF1in cervical carcinoma, and to determine the relationship between the expression of the three proteins and tumor clinicopathological features. Methods The expres-sion of Plk1, Cyclin B1 and p21WAF1 was detected in 102 cases of cervical carcinoma, 20 cases of (cervical intraepithelial neoplasia, CIN) , and 20 cases of nomal cervical tissues by the technique of tissue chip and immunohistochemical staining of EliVision. Statistical analyses of the data were performed with SPSS 19. 0 software. Results The positive rates of Plk1 in cervical carcinoma and CIN were 70. 5%, 55. 0%, respectively, which were significantly higher than normal cervical tissues (10%) (P<0. 01);The positive rates of Cyclin B1 in cervical carcinoma and CIN were 52. 9% and 30. 0%, respectively, which were significantly higher than normal cervical tissues (10%)(P <0.01); The positive rates of p21WAF1 in cervical carcinoma and CIN were 23.5% and 10.0%, respectively, which were significantly higher than normal cervical tissues ( 0 ) ( P<0. 01 ) . There were no significant differences between cervical carcinoma and CIN in the positive rates of Plk1, Cyclin B1 and p21WAF1. The expression of Plk1 was associated with the depth of carci-noma invasion (P<0. 05), that of Cyclin B1 was associated with lymph node metastases and the depth of carcinoma invasion (P<0. 05)and that of p21WAF1 in cervical carcinoma was associated with histological grade (P<0. 05). In cervical carcinoma, the expres-sion of Plk1 was positively correlated with Cyclin B1 (rs =0. 297, P=0. 002) and negatively correlated with p21WAF1(rs = -0. 403, P<0. 001). Conclusion The expression of Plk1, Cyclin B1 and p21WAF1 is involved in the occurrence and development of cervical carcinoma, and the former two are also related with prognosis of cervical carcinoma. The combination of the three would provide a new target for clinical treatment.
2.The influence of treating course on the Hpid-regulating effect of Xuezhikang and Simvastati
Qiuye TENG ; Zhaoli TANG ; Biyun QIN ; Zhikun ZHANG ; Hailian TANG ; Haiyu CHENG
Clinical Medicine of China 2011;27(9):910-913
ObjectiveTo observe the influence of treating course on the lipid-regulating effect of Xuezhikang and Simvastati.MethodsTwo hundred and two patients with unstable angina pectoris(UAP) were randomly enrolled and divided into Simvastatin group(n = 98)and Xuezhikang group(n = 104).The TC, TG,LDL-C, HDL-Clevelsweremeasuredbeforethe treatment and atthe3rd, 6thmonthafter the treatment.According to the suitable threshold of blood lipids in normal Chinese people, the patients who had abnormal blood lipids were picked out from the two groups for the further observation.ResultsThe lipidregulating effects of Simvastatin and Xuezhikang were showed up at the 3rd month, and the effective rate were 40.6% and 60.9% for TC regulation,51.2% and 84.5% for LDL-C regulation,22.2% and 61.5% for HDL-C regulation.We found significantly better effects of Xuezhikang than that of Simvastatin(x2 = 6.38,17.05,4.04;P < 0.05, P < 0.01, P < 0.05) .However, at the 6th month the effective rate of Simvastatin and Xuezhikang were 89.9% and 95.4% for TC regulation,89.1% and 97.2% for LDL-C regulation,83.3% and 84.6% for HDL-C regulation, which showed no significant differences (x2 = 1.81,3.57, 0.01 ; Ps > 0.05).The effective percentages of reduced TG level of Simvastatin and Xuezhikang were 9.5% and 24.5% at the 3rd month,51.4% and 68.4% at the 6th month, which showed significant differences (x2 = 6.45,5.13 ; Ps < 0.05) between the two groups at both time points.Conclusion The lipid-regulating effects of Xuezhikang and Simvastati were influenced by the treating period.Xuezhikang shows lipid-regulating effect more quickly ,and it is recommended in treating CHD patients,especially for the patients with hypertriglyceridemia.
3.Nursing care of the ex-utero intrapartum treatment in one case fetal neck mass oppressing airway
Liyan ZHAO ; Hailian CHAO ; Bianni QIN ; Lina WU ; Bo LI ; Huili ZHAO ; Rongli HE ; Qing GAO ; Xiongtao LIU
Chinese Journal of Practical Nursing 2016;32(32):2528-2530
Objective To explore nursing care of the ex-utero intrapartum treatment (EXIT) in fetal neck mass oppressing airway. Methods A case of EXIT in which a fetal neck mass was diagnosed on ultrasound was fully prepared supplies and carried out. Nursing care was well implemented and vital signs of the puerpera and fetus were observed in preoperative and intraoperative surgery. Results The EXIT procedure was successful performed and vital signs of the puerpera and fetus were steadied. The score of Apgar was seven to eight. Conclusions Adequate equipment, multi-department collaboration, preoperative exercise and close cooperation are the important guarantee for the success of ex-utero intrapartum treatment.
4.Expression and prognostic significance of cell division cycle associated protein 5 in pancreatic cancer tissues
Shuzhen LI ; Xianqing ZHOU ; Wei WEI ; Yan YI ; Runyao MA ; Tong YANG ; Hailian QIN ; Guiqi YANG
Cancer Research and Clinic 2023;35(4):286-290
Objective:To analyze the expression of cell division cycle associated protein 5 (CDCA5) in pancreatic cancer tissues and its correlation with prognosis based on the bioinformatics.Methods:The RNA sequencing data (HTSeq-FPKM) and corresponding clinical information of 168 pancreatic cancer samples from January to December 2021 were downloaded from the Cancer Genome Atlas (TCGA) database, and the data of 179 pancreatic patients from January to December 2021 were downloaded from the GEPIA2 database, and 171 normal pancreatic tissues from TCGA and GTEx databases were simultaneously integrated. The relative expression level of CDCA5 mRNA in pancreatic cancer patients in GEPIA2 database and its relationship with overall survival (OS) and disease-free survival (DFS) were explored. Combined with the clinical data of the patients, univariate and multivariate Cox regression model analysis was used to analyze the factors influencing the OS of pancreatic cancer patients. Gene set enrichment analysis (GSEA) was performed to investigate the possibly involved signal pathways of CDCA5 in pancreatic cancer.Results:In the GEPIA2 database, the relative expression level of CDCA5 mRNA in pancreatic cancer tissues was higher than that in normal pancreatic tissues, and the difference was statistically significant ( P < 0.05). The pancreatic cancer patients were divided into the high CDCA5 mRNA expression group (89 cases) and the low CDCA5 mRNA expression group (89 cases) according to the median of relative expression level of CDCA5 mRNA (the case equal to the median value was not subgrouped). Survival analysis showed that patients with high CDCA5 mRNA expression had shorter OS ( P = 0.024) and DFS ( P = 0.025) compared with those with low CDCA5 mRNA expression. Multivariate Cox analysis showed that in TCGA database, N staging ( HR = 2.15, 95% CI 1.24-3.72, P = 0.006) and CDCA5 expression ( HR = 1.71, 95% CI 1.23-2.38, P = 0.001) were independent influencing factors of OS for pancreatic cancer patients. The results of GSEA enrichment analysis indicated that high CDCA5 mRNA expression was enriched in 13 biological pathways [all P < 0.05, false discovery rate (FDR) < 0.005] including cell cycle, DNA replication, homologous recombination, pyrimidine metabolism, mismatch repair, pentose phosphate pathway, glycolysis gluconeogenesis and p53. The expression of CDCA5 mRNA was positively correlated with the expressions of HK2, PKM, PGK1, ALDOA, EN01 and LDHA (all P < 0.05). Conclusions:CDCA5 is highly expressed in pancreatic cancer tissues and is associated with poor prognosis of patients, and it can be used as a prognostic marker for pancreatic cancer.